Yonsei Med J.  2014 Jan;55(1):78-83. 10.3349/ymj.2014.55.1.78.

Clinical Experiences of Incidental Prostate Cancer after Transurethral Resection of Prostate (TURP) According to Initial Treatment: A Study of a Korean High Volume Center

• Lee DH
• Chung DY
• Lee KS
• Kim IK
• Rha KH
• Choi YD
• Chung BH
• Hong SJ
• Kim JH

• KMID: 1779889
• DOI: http://doi.org/10.3349/ymj.2014.55.1.78

Abstract

PURPOSE
These are the clinical experiences of Korean incidental prostate cancer patients detected by transurethral resection of the prostate according to initial treatment: active surveillance (AS), radical prostatectomy (RP) and hormone therapy (HT).
MATERIALS AND METHODS
We retrospectively reviewed the records of 156 incidental prostate cancer patients between 2001 and 2012. The clinicopathologic outcomes were reviewed and follow-up results were obtained.
RESULTS
Among 156 patients, 97 (62.2%) had T1a and 59 (37.8%) had T1b. Forty-six (29.5%) received AS, 67 (42.9%) underwent RP, 34 (21.8%) received HT, 4 (2.6%) received radiotherapy, and 5 (3.2%) chose watchful waiting. Of 46 patients on AS, prostate-specific antigen (PSA) progression occurred in 12 (26.1%) patients. Among them, 3 patients refused treatment despite PSA progression. Five patients, who underwent RP as an intervention, all had organ-confined Gleason score < or =6 disease. In 67 patients who underwent RP, 50 (74.6%) patients had insignificant prostate cancer and 8 (11.9%) patients showed unfavorable features. During follow-up, biochemical recurrence occurred in 2 patients. Among 34 patients who received HT, 3 (8.8%) patients had PSA progression. Among 156 patients, 6 patients died due to other causes during follow-up. There were no patients who died due to prostate cancer.
CONCLUSION
The clinical outcomes of incidental prostate cancer were satisfactory regardless of the initial treatment. However, according to recent researches and guidelines, immediate definite therapy should be avoided without a careful assessment. We also believe that improved clinical staging is needed for these patients.

Keyword

Incidental prostate cancer; radical prostatectomy; active surveillance

MeSH Terms

Aged
Humans
Korea
Male
Middle Aged
Prostatectomy
Prostatic Neoplasms/*surgery
Retrospective Studies
Transurethral Resection of Prostate/*methods

Reference

1. Capitanio U. Contemporary management of patients with T1a and T1b prostate cancer. Curr Opin Urol. 2011; 21:252–256.

2. Zigeuner RE, Lipsky K, Riedler I, Auprich M, Schips L, Salfellner M, et al. Did the rate of incidental prostate cancer change in the era of PSA testing? A retrospective study of 1127 patients. Urology. 2003; 62:451–455.

3. Cheng L, Bergstralh EJ, Scherer BG, Neumann RM, Blute ML, Zincke H, et al. Predictors of cancer progression in T1a prostate adenocarcinoma. Cancer. 1999; 85:1300–1304.

4. Jewett HJ. The present status of radical prostatectomy for stages A and B prostatic cancer. Urol Clin North Am. 1975; 2:105–124.

5. Cantrell BB, DeKlerk DP, Eggleston JC, Boitnott JK, Walsh PC. Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade. J Urol. 1981; 125:516–520.

6. Magheli A, Rais-Bahrami S, Carter HB, Peck HJ, Epstein JI, Gonzalgo ML. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy. J Urol. 2007; 178(4 Pt 1):1277–1280.

7. Capitanio U, Briganti A, Suardi N, Gallina A, Salonia A, Freschi M, et al. When should we expect no residual tumor (pT0) once we submit incidental T1a-b prostate cancers to radical prostatectomy? Int J Urol. 2011; 18:148–153.

8. Jones JS, Follis HW, Johnson JR. Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era. Prostate Cancer Prostatic Dis. 2009; 12:57–60.

9. Andrèn O, Garmo H, Mucci L, Andersson SO, Johansson JE, Fall K. Incidence and mortality of incidental prostate cancer: a Swedish register-based study. Br J Cancer. 2009; 100:170–173.

10. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011; 59:61–71.

11. Descazeaud A, Peyromaure M, Salin A, Amsellem-Ouazana D, Flam T, Viellefond A, et al. Predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era. Eur Urol. 2008; 53:355–361.

12. Epstein JI, Paull G, Eggleston JC, Walsh PC. Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup. J Urol. 1986; 136:837–839.

13. Paulson DF, Moul JW, Walther PJ. Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. J Urol. 1990; 144:1180–1184.

14. Masue N, Deguchi T, Nakano M, Ehara H, Uno H, Takahashi Y. Retrospective study of 101 cases with incidental prostate cancer stages T1a and T1b. Int J Urol. 2005; 12:1045–1049.

15. Lefi M, Hellara W, Touffahi M, Fredj N, Adnene M, Saidi R, et al. [Prostate cancer: comparative study of stage T1a and stage T1b]. Prog Urol. 2007; 17:1343–1346.

16. Capitanio U, Scattoni V, Freschi M, Briganti A, Salonia A, Gallina A, et al. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. Eur Urol. 2008; 54:118–125.

17. Adolfsson J. The management of category T1a-T1b (incidental) prostate cancer: can we predict who needs treatment? Eur Urol. 2008; 54:16–18.

18. Melchior S, Hadaschik B, Thüroff S, Thomas C, Gillitzer R, Thüroff J. Outcome of radical prostatectomy for incidental carcinoma of the prostate. BJU Int. 2009; 103:1478–1481.

19. Capitanio U, Cheng L, Lopez-Beltran A, Scarpelli M, Freschi M, Montorsi F, et al. The importance of interaction between urologists and pathologists in incidental prostate cancer management. Eur Urol. 2011; 60:75–77.

20. Rajab R, Fisher G, Kattan MW, Foster CS, Møller H, Oliver T, et al. An improved prognostic model for stage T1a and T1b prostate cancer by assessments of cancer extent. Mod Pathol. 2011; 24:58–63.